ADNI Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion (DE&I) Working Group: A new collaboration that crosses boundaries for industry, academia, and under‐represented patients

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion Working Group (DE&I WG) was established to work with the ADNI3 Diversity Task Force to provide an industry perspective on increasing the representation of diverse participants in ADNI3 and to build precompetitive cross‐industry knowledge in engagement and recruitment of under‐represented participants (URPs). In this article, we review and highlight the role and ongoing activities within the ADNI PPSB DE&I WG and provide a cross‐industry perspective on areas where precompetitive collaboration can improve the inclusiveness in clinical trials, drawing on examples from ADNI4.Highlights New collaboration crosses boundaries to allow PPSB DE&I WG members to work together in a preproprietary way. When faced with the same challenges required by FDA combined with a growing prevalence of AD, the DE&I WG has drafted a range of initiatives that may benefit ADNI, AD patients, care partners, and respective companies involved in this work. In order to address the multifactorial problem of successfully enrolling representative populations in clinical trials, it will “take a village” to bring about sustainable changes.